Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug
A new Alzheimer's drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by coverage questions and conc…
A new Alzheimer's drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated by coverage questions and conc…